Gary L. Rosner, ScD, on Bayesian Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Nov

Today In Oncology

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible

ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer

FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer

Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women

Large AI Breast Cancer Screening Trial Increases Detection Rate